English

AbCellera Biologics Inc.

EDGAR

ABCL Quarterly report (10-Q) · filed 2026-08-05

Annual consolidated revenue for 2025: about USD 75.13M, using the latest reported figures. The previous period, 2024, was about USD 28.83M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

4.05 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 4050000 USD Source

Operating margin

-1,550.05%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -62777000 USD Source
Revenue: 4050000 USD Source

Operating cash flow

25.9 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -7600000 USD Source
Operating Cash Flow: -33523000 USD Source

Free cash flow

23.8 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -7600000 USD Source
Operating Cash Flow: -33523000 USD Source
Capital Expenditure: 5963000 USD Source
Capital Expenditure: 3831000 USD Source

Cash and cash equivalents: 120 million USD 2026-06-30 Source
Exact value

120065000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 306 million shares 2026-06-30 Source
Exact value

306469632 shares

Reported share-count change

3.62% · 10.7 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

295757002 shares · 2025-06-30· Source
306469632 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

66.2 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 8955000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 75128000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 30275000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 8315000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 4050000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-165 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -57119000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -146412000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -137467000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -43165000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -55427000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-94.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -96552000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -43958000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -131295000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -96552000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -33523000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -7600000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -33523000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

24.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 32929000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 24001000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 42772000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 32929000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3831000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 5963000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 3831000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-120 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -96552000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -43958000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -131295000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -96552000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -33523000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -7600000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -33523000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 32929000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 24001000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 42772000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 32929000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3831000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 5963000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 3831000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-05.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+160.6%

Prior period

USD 28.83 million

2024-01-01 – 2024-12-31
Current period

USD 75.13 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

75128000 − 28833000 = 46295000 USD

28833000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
75128000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · AbCellera Biologics Inc. · 2025-12-31 AbCellera Biologics Inc. (edgar:1703057) Year-over-year change in Revenue: 46295000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 75128000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1390959 Filing: 000170305726000012 Input fundies:Revenue: 28833000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1390296 Filing: 000170305726000012
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 16.45 million

Prior period

−USD 162.86 million

2024-01-01 – 2024-12-31
Current period

−USD 146.41 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-146412000 − -162857000 = 16445000 USD

-162857000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-146412000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · AbCellera Biologics Inc. · 2025-12-31 AbCellera Biologics Inc. (edgar:1703057) Year-over-year change in Net income: 16445000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -146412000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1491274 Filing: 000170305726000012 Input fundies:NetIncome: -162857000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1474451 Filing: 000170305726000012
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 22.74 million

Prior period

−USD 108.56 million

2024-01-01 – 2024-12-31
Current period

−USD 131.3 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-131295000 − -108556000 = -22739000 USD

-108556000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-131295000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · AbCellera Biologics Inc. · 2025-12-31 AbCellera Biologics Inc. (edgar:1703057) Year-over-year change in Operating cash flow: -22739000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -131295000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1530863 Filing: 000170305726000012 Input fundies:OperatingCashFlow: -108556000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1530210 Filing: 000170305726000012
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-45.4%

Prior period

USD 78.4 million

2024-01-01 – 2024-12-31
Current period

USD 42.77 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

42772000 − 78396000 = -35624000 USD

78396000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
42772000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · AbCellera Biologics Inc. · 2025-12-31 AbCellera Biologics Inc. (edgar:1703057) Year-over-year change in Capital expenditure: -35624000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 42772000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1533632 Filing: 000170305726000012 Input fundies:CapitalExpenditure: 78396000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1533041 Filing: 000170305726000012
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 75.13 million 100% of revenue
Operating costs Derived USD 292.23 million 389% of revenue
Operating income −USD 217.1 million −289% of revenue
Tax, interest and other Derived −USD 70.69 million −94% of revenue
Net income −USD 146.41 million −195% of revenue

Cash

Operating cash flow −USD 131.3 million −175% of revenue
Capital expenditure USD 42.77 million 57% of revenue
Free cash flow Derived −USD 174.07 million −232% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 135% of revenue.
2020 51%16%33%
2021 41%14%46%
2022 33%12%55%
2023 Operating loss: operating costs were 724% of revenue.
2024 Operating loss: operating costs were 1,192% of revenue.
2025 Operating loss: operating costs were 389% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	11612000	15729000 Derived	-4117000	-1906000 Derived	-2211000	-1303000 Derived	Source 2019-01-01 – 2019-12-31: 11612000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -4117000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -2211000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 2694000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 3997000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	233155000	77124000 Derived	156031000	37113000 Derived	118918000	13017000 Derived	Source 2020-01-01 – 2020-12-31: 233155000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 156031000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 118918000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 22690000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 9673000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	375203000	170790000 Derived	204413000	50949000 Derived	153464000	186132000 Derived	Source 2021-01-01 – 2021-12-31: 375203000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 204413000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 153464000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 244584000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 58452000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	485424000	268913000 Derived	216511000	57992000 Derived	158519000	206700000 Derived	Source 2022-01-01 – 2022-12-31: 485424000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: 216511000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 158519000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 277360000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 70660000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	38025000	275232000 Derived	-237207000	-90809000 Derived	-146398000	-120824000 Derived	Source 2023-01-01 – 2023-12-31: 38025000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -237207000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -146398000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -43877000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 76947000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	28833000	343599000 Derived	-314766000	-151909000 Derived	-162857000	-186952000 Derived	Source 2024-01-01 – 2024-12-31: 28833000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -314766000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -162857000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -108556000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 78396000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	75128000	292231000 Derived	-217103000	-70691000 Derived	-146412000	-174067000 Derived	Source 2025-01-01 – 2025-12-31: 75128000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -217103000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -146412000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -131295000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 42772000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 75.1M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	11612000	Revenue: 11612000 Open source
20202020-12-31	Revenue	233155000	Revenue: 233155000 Open source
20212021-12-31	Revenue	375203000	Revenue: 375203000 Open source
20222022-12-31	Revenue	485424000	Revenue: 485424000 Open source
20232023-12-31	Revenue	38025000	Revenue: 38025000 Open source
20242024-12-31	Revenue	28833000	Revenue: 28833000 Open source
20252025-12-31	Revenue	75128000	Revenue: 75128000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

160.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 11612000 Open source
20202020-12-31	Year over year	1,907.9%	Revenue: 233155000 Open source Revenue: 11612000 Open source
20212021-12-31	Year over year	60.9%	Revenue: 375203000 Open source Revenue: 233155000 Open source
20222022-12-31	Year over year	29.4%	Revenue: 485424000 Open source Revenue: 375203000 Open source
20232023-12-31	Year over year	-92.2%	Revenue: 38025000 Open source Revenue: 485424000 Open source
20242024-12-31	Year over year	-24.2%	Revenue: 28833000 Open source Revenue: 38025000 Open source
20252025-12-31	Year over year	160.6%	Revenue: 75128000 Open source Revenue: 28833000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -289% 2025

Net margin -194.9% 2025

Free cash flow margin -231.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-35.5%	Operating Income: -4117000 Open source Revenue: 11612000 Open source
20202020-12-31	Operating margin	66.9%	Operating Income: 156031000 Open source Revenue: 233155000 Open source
20212021-12-31	Operating margin	54.5%	Operating Income: 204413000 Open source Revenue: 375203000 Open source
20222022-12-31	Operating margin	44.6%	Operating Income: 216511000 Open source Revenue: 485424000 Open source
20232023-12-31	Operating margin	-623.8%	Operating Income: -237207000 Open source Revenue: 38025000 Open source
20242024-12-31	Operating margin	-1,091.7%	Operating Income: -314766000 Open source Revenue: 28833000 Open source
20252025-12-31	Operating margin	-289%	Operating Income: -217103000 Open source Revenue: 75128000 Open source
20192019-12-31	Net margin	-19%	Net Income: -2211000 Open source Revenue: 11612000 Open source
20202020-12-31	Net margin	51%	Net Income: 118918000 Open source Revenue: 233155000 Open source
20212021-12-31	Net margin	40.9%	Net Income: 153464000 Open source Revenue: 375203000 Open source
20222022-12-31	Net margin	32.7%	Net Income: 158519000 Open source Revenue: 485424000 Open source
20232023-12-31	Net margin	-385%	Net Income: -146398000 Open source Revenue: 38025000 Open source
20242024-12-31	Net margin	-564.8%	Net Income: -162857000 Open source Revenue: 28833000 Open source
20252025-12-31	Net margin	-194.9%	Net Income: -146412000 Open source Revenue: 75128000 Open source
20192019-12-31	Free cash flow margin	-11.2%	Revenue: 11612000 Open source Operating Cash Flow: 2694000 Open source Capital Expenditure: 3997000 Open source
20202020-12-31	Free cash flow margin	5.6%	Revenue: 233155000 Open source Operating Cash Flow: 22690000 Open source Capital Expenditure: 9673000 Open source
20212021-12-31	Free cash flow margin	49.6%	Revenue: 375203000 Open source Operating Cash Flow: 244584000 Open source Capital Expenditure: 58452000 Open source
20222022-12-31	Free cash flow margin	42.6%	Revenue: 485424000 Open source Operating Cash Flow: 277360000 Open source Capital Expenditure: 70660000 Open source
20232023-12-31	Free cash flow margin	-317.7%	Revenue: 38025000 Open source Operating Cash Flow: -43877000 Open source Capital Expenditure: 76947000 Open source
20242024-12-31	Free cash flow margin	-648.4%	Revenue: 28833000 Open source Operating Cash Flow: -108556000 Open source Capital Expenditure: 78396000 Open source
20252025-12-31	Free cash flow margin	-231.7%	Revenue: 75128000 Open source Operating Cash Flow: -131295000 Open source Capital Expenditure: 42772000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -131.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	2694000	Operating Cash Flow: 2694000 Open source
20202020-12-31	Operating cash flow	22690000	Operating Cash Flow: 22690000 Open source
20212021-12-31	Operating cash flow	244584000	Operating Cash Flow: 244584000 Open source
20222022-12-31	Operating cash flow	277360000	Operating Cash Flow: 277360000 Open source
20232023-12-31	Operating cash flow	-43877000	Operating Cash Flow: -43877000 Open source
20242024-12-31	Operating cash flow	-108556000	Operating Cash Flow: -108556000 Open source
20252025-12-31	Operating cash flow	-131295000	Operating Cash Flow: -131295000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -174.1M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-1303000	Operating Cash Flow: 2694000 Open source Capital Expenditure: 3997000 Open source
20202020-12-31	Free cash flow	13017000	Operating Cash Flow: 22690000 Open source Capital Expenditure: 9673000 Open source
20212021-12-31	Free cash flow	186132000	Operating Cash Flow: 244584000 Open source Capital Expenditure: 58452000 Open source
20222022-12-31	Free cash flow	206700000	Operating Cash Flow: 277360000 Open source Capital Expenditure: 70660000 Open source
20232023-12-31	Free cash flow	-120824000	Operating Cash Flow: -43877000 Open source Capital Expenditure: 76947000 Open source
20242024-12-31	Free cash flow	-186952000	Operating Cash Flow: -108556000 Open source Capital Expenditure: 78396000 Open source
20252025-12-31	Free cash flow	-174067000	Operating Cash Flow: -131295000 Open source Capital Expenditure: 42772000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

28.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2019-12-31	Liabilities / assets	Not reported	No source recorded
20202020-12-31	Liabilities / assets	17.4%	Total Liabilities: 175028000 Open source Total Assets: 1005536000 Open source
20212021-12-31	Liabilities / assets	22.2%	Total Liabilities: 292836000 Open source Total Assets: 1318569000 Open source
20222022-12-31	Liabilities / assets	20%	Total Liabilities: 307630000 Open source Total Assets: 1540907000 Open source
20232023-12-31	Liabilities / assets	22.6%	Total Liabilities: 335776000 Open source Total Assets: 1488094000 Open source
20242024-12-31	Liabilities / assets	22.4%	Total Liabilities: 304469000 Open source Total Assets: 1360553000 Open source
20252025-12-31	Liabilities / assets	28.7%	Total Liabilities: 390046000 Open source Total Assets: 1356950000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

11.32× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2019-12-31	Current assets / current liabilities	Not reported	No source recorded
20202020-12-31	Current assets / current liabilities	7.86×	Current Assets: 813325000 Open source Current Liabilities: 103490000 Open source
20212021-12-31	Current assets / current liabilities	7.7×	Current Assets: 929800000 Open source Current Liabilities: 120676000 Open source
20222022-12-31	Current assets / current liabilities	8.67×	Current Assets: 1025491000 Open source Current Liabilities: 118320000 Open source
20232023-12-31	Current assets / current liabilities	7.33×	Current Assets: 871985000 Open source Current Liabilities: 119013000 Open source
20242024-12-31	Current assets / current liabilities	9.81×	Current Assets: 751370000 Open source Current Liabilities: 76612000 Open source
20252025-12-31	Current assets / current liabilities	11.32×	Current Assets: 728232000 Open source Current Liabilities: 64307000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 2.21 million Exact value Exact value: -2211000 USD 2019-01-01 – 2019-12-31: -2211000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AbCellera Biologics Inc. · 2019-12-31 AbCellera Biologics Inc. (edgar:1703057) Net Income: -2211000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2211000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000156459022007077/abcl-10k_20211231.htm#3631352 Filing: 000156459022007077 The citation records this snapshot. The page link may show a newer release later.	USD 2.69 million Exact value Exact value: 2694000 USD 2019-01-01 – 2019-12-31: 2694000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AbCellera Biologics Inc. · 2019-12-31 AbCellera Biologics Inc. (edgar:1703057) Operating Cash Flow: 2694000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 2694000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000156459022007077/abcl-10k_20211231.htm#3358488 Filing: 000156459022007077 The citation records this snapshot. The page link may show a newer release later.	USD 4 million Exact value Exact value: 3997000 USD 2019-01-01 – 2019-12-31: 3997000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AbCellera Biologics Inc. · 2019-12-31 AbCellera Biologics Inc. (edgar:1703057) Capital Expenditure: 3997000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3997000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000156459022007077/abcl-10k_20211231.htm#3370198 Filing: 000156459022007077 The citation records this snapshot. The page link may show a newer release later.	−USD 1.3 million Calculation and evidence 2694000 − 3997000 USD Exact free cash flow: -1303000 USD 2019-01-01 – 2019-12-31: 2694000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 3997000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AbCellera Biologics Inc. · 2019-12-31 AbCellera Biologics Inc. (edgar:1703057) Free cash flow: -1303000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 2694000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000156459022007077/abcl-10k_20211231.htm#3358488 Filing: 000156459022007077 Input fundies:CapitalExpenditure: 3997000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000156459022007077/abcl-10k_20211231.htm#3370198 Filing: 000156459022007077 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 118.92 million Exact value Exact value: 118918000 USD 2020-01-01 – 2020-12-31: 118918000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AbCellera Biologics Inc. · 2020-12-31 AbCellera Biologics Inc. (edgar:1703057) Net Income: 118918000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 118918000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000156459023002128/abcl-10k_20221231.htm#3450410 Filing: 000156459023002128 The citation records this snapshot. The page link may show a newer release later.	USD 22.69 million Exact value Exact value: 22690000 USD 2020-01-01 – 2020-12-31: 22690000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AbCellera Biologics Inc. · 2020-12-31 AbCellera Biologics Inc. (edgar:1703057) Operating Cash Flow: 22690000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 22690000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000156459023002128/abcl-10k_20221231.htm#3183875 Filing: 000156459023002128 The citation records this snapshot. The page link may show a newer release later.	USD 9.67 million Exact value Exact value: 9673000 USD 2020-01-01 – 2020-12-31: 9673000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AbCellera Biologics Inc. · 2020-12-31 AbCellera Biologics Inc. (edgar:1703057) Capital Expenditure: 9673000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9673000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000156459023002128/abcl-10k_20221231.htm#3195344 Filing: 000156459023002128 The citation records this snapshot. The page link may show a newer release later.	USD 13.02 million Calculation and evidence 22690000 − 9673000 USD Exact free cash flow: 13017000 USD 2020-01-01 – 2020-12-31: 22690000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 9673000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AbCellera Biologics Inc. · 2020-12-31 AbCellera Biologics Inc. (edgar:1703057) Free cash flow: 13017000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 22690000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000156459023002128/abcl-10k_20221231.htm#3183875 Filing: 000156459023002128 Input fundies:CapitalExpenditure: 9673000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000156459023002128/abcl-10k_20221231.htm#3195344 Filing: 000156459023002128 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 153.46 million Exact value Exact value: 153464000 USD 2021-01-01 – 2021-12-31: 153464000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AbCellera Biologics Inc. · 2021-12-31 AbCellera Biologics Inc. (edgar:1703057) Net Income: 153464000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 153464000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305724000019/abcl-20231231.htm#1545419 Filing: 000170305724000019 The citation records this snapshot. The page link may show a newer release later.	USD 244.58 million Exact value Exact value: 244584000 USD 2021-01-01 – 2021-12-31: 244584000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AbCellera Biologics Inc. · 2021-12-31 AbCellera Biologics Inc. (edgar:1703057) Operating Cash Flow: 244584000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 244584000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305724000019/abcl-20231231.htm#1618842 Filing: 000170305724000019 The citation records this snapshot. The page link may show a newer release later.	USD 58.45 million Exact value Exact value: 58452000 USD 2021-01-01 – 2021-12-31: 58452000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AbCellera Biologics Inc. · 2021-12-31 AbCellera Biologics Inc. (edgar:1703057) Capital Expenditure: 58452000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 58452000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305724000019/abcl-20231231.htm#1621518 Filing: 000170305724000019 The citation records this snapshot. The page link may show a newer release later.	USD 186.13 million Calculation and evidence 244584000 − 58452000 USD Exact free cash flow: 186132000 USD 2021-01-01 – 2021-12-31: 244584000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 58452000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AbCellera Biologics Inc. · 2021-12-31 AbCellera Biologics Inc. (edgar:1703057) Free cash flow: 186132000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 244584000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305724000019/abcl-20231231.htm#1618842 Filing: 000170305724000019 Input fundies:CapitalExpenditure: 58452000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305724000019/abcl-20231231.htm#1621518 Filing: 000170305724000019 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	USD 158.52 million Exact value Exact value: 158519000 USD 2022-01-01 – 2022-12-31: 158519000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AbCellera Biologics Inc. · 2022-12-31 AbCellera Biologics Inc. (edgar:1703057) Net Income: 158519000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 158519000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000162828025008689/abcl-20241231.htm#1556122 Filing: 000162828025008689 The citation records this snapshot. The page link may show a newer release later.	USD 277.36 million Exact value Exact value: 277360000 USD 2022-01-01 – 2022-12-31: 277360000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AbCellera Biologics Inc. · 2022-12-31 AbCellera Biologics Inc. (edgar:1703057) Operating Cash Flow: 277360000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 277360000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000162828025008689/abcl-20241231.htm#1631352 Filing: 000162828025008689 The citation records this snapshot. The page link may show a newer release later.	USD 70.66 million Exact value Exact value: 70660000 USD 2022-01-01 – 2022-12-31: 70660000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AbCellera Biologics Inc. · 2022-12-31 AbCellera Biologics Inc. (edgar:1703057) Capital Expenditure: 70660000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 70660000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000162828025008689/abcl-20241231.htm#1634265 Filing: 000162828025008689 The citation records this snapshot. The page link may show a newer release later.	USD 206.7 million Calculation and evidence 277360000 − 70660000 USD Exact free cash flow: 206700000 USD 2022-01-01 – 2022-12-31: 277360000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 70660000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AbCellera Biologics Inc. · 2022-12-31 AbCellera Biologics Inc. (edgar:1703057) Free cash flow: 206700000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 277360000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000162828025008689/abcl-20241231.htm#1631352 Filing: 000162828025008689 Input fundies:CapitalExpenditure: 70660000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000162828025008689/abcl-20241231.htm#1634265 Filing: 000162828025008689 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 146.4 million Exact value Exact value: -146398000 USD 2023-01-01 – 2023-12-31: -146398000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AbCellera Biologics Inc. · 2023-12-31 AbCellera Biologics Inc. (edgar:1703057) Net Income: -146398000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -146398000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1457383 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.	−USD 43.88 million Exact value Exact value: -43877000 USD 2023-01-01 – 2023-12-31: -43877000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AbCellera Biologics Inc. · 2023-12-31 AbCellera Biologics Inc. (edgar:1703057) Operating Cash Flow: -43877000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43877000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1529558 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.	USD 76.95 million Exact value Exact value: 76947000 USD 2023-01-01 – 2023-12-31: 76947000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AbCellera Biologics Inc. · 2023-12-31 AbCellera Biologics Inc. (edgar:1703057) Capital Expenditure: 76947000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 76947000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1532450 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.	−USD 120.82 million Calculation and evidence -43877000 − 76947000 USD Exact free cash flow: -120824000 USD 2023-01-01 – 2023-12-31: -43877000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 76947000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AbCellera Biologics Inc. · 2023-12-31 AbCellera Biologics Inc. (edgar:1703057) Free cash flow: -120824000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43877000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1529558 Filing: 000170305726000012 Input fundies:CapitalExpenditure: 76947000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1532450 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 162.86 million Exact value Exact value: -162857000 USD 2024-01-01 – 2024-12-31: -162857000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AbCellera Biologics Inc. · 2024-12-31 AbCellera Biologics Inc. (edgar:1703057) Net Income: -162857000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -162857000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1474451 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.	−USD 108.56 million Exact value Exact value: -108556000 USD 2024-01-01 – 2024-12-31: -108556000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AbCellera Biologics Inc. · 2024-12-31 AbCellera Biologics Inc. (edgar:1703057) Operating Cash Flow: -108556000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -108556000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1530210 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.	USD 78.4 million Exact value Exact value: 78396000 USD 2024-01-01 – 2024-12-31: 78396000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AbCellera Biologics Inc. · 2024-12-31 AbCellera Biologics Inc. (edgar:1703057) Capital Expenditure: 78396000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 78396000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1533041 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.	−USD 186.95 million Calculation and evidence -108556000 − 78396000 USD Exact free cash flow: -186952000 USD 2024-01-01 – 2024-12-31: -108556000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 78396000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AbCellera Biologics Inc. · 2024-12-31 AbCellera Biologics Inc. (edgar:1703057) Free cash flow: -186952000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -108556000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1530210 Filing: 000170305726000012 Input fundies:CapitalExpenditure: 78396000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1533041 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 146.41 million Exact value Exact value: -146412000 USD 2025-01-01 – 2025-12-31: -146412000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AbCellera Biologics Inc. · 2025-12-31 AbCellera Biologics Inc. (edgar:1703057) Net Income: -146412000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -146412000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1491274 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.	−USD 131.3 million Exact value Exact value: -131295000 USD 2025-01-01 – 2025-12-31: -131295000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AbCellera Biologics Inc. · 2025-12-31 AbCellera Biologics Inc. (edgar:1703057) Operating Cash Flow: -131295000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -131295000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1530863 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.	USD 42.77 million Exact value Exact value: 42772000 USD 2025-01-01 – 2025-12-31: 42772000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AbCellera Biologics Inc. · 2025-12-31 AbCellera Biologics Inc. (edgar:1703057) Capital Expenditure: 42772000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 42772000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1533632 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.	−USD 174.07 million Calculation and evidence -131295000 − 42772000 USD Exact free cash flow: -174067000 USD 2025-01-01 – 2025-12-31: -131295000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 42772000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AbCellera Biologics Inc. · 2025-12-31 AbCellera Biologics Inc. (edgar:1703057) Free cash flow: -174067000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:39:40Z Snapshot: 3510c24dde734813a5e647c18dde820fbaf794dbd38d2c70df64af7189235352 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1703057?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -131295000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1530863 Filing: 000170305726000012 Input fundies:CapitalExpenditure: 42772000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm#1533632 Filing: 000170305726000012 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

30 filings · 1,795 latest values · 1,795 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001703057, 1703057, ABCL, edgar:1703057

Also known as AbCellera Biologics Inc.

AbCellera Biologics Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation